[Featured Stock] Genome & Company "Technology Transfer to Swiss Pharmaceutical Company"... Limit Up

The stock price of Genome&Company, which signed a technology transfer contract for the antibody-drug conjugate (ADC) substance 'GENA 111' with a Swiss pharmaceutical company, hit the upper limit.

As of 9:28 a.m. on the 3rd, Genome&Company was trading at 11,840 won, up 2,730 won (29.97%) from the previous trading day.

On this day, Genome&Company announced, "We have signed a technology transfer contract with the Swiss pharmaceutical company Diviopharm." A representative of Genome&Company explained, "We are transferring exclusive rights to Diviopharm for the development and commercialization of 'GENA 111-based ADC,' which combines Diviopharm's ADC platform technology with the antibody GENA 111 based on the new target 'CD239.'"

This is the first technology transfer in the new target anticancer drug field for Genome&Company. The contract size is approximately $426 million (about 586.4 billion won), including an upfront payment of $5 million (about 690 million won) and milestones (stage-based royalties).

This content was produced with the assistance of AI translation services.